Futura Medical PLC Futura Medical Announces Investor Seminar (0215C)
08 Junho 2023 - 3:00AM
UK Regulatory
TIDMFUM
RNS Number : 0215C
Futura Medical PLC
08 June 2023
8 June 2023
Futura Medical plc
("Futura" or the "Company")
Futura Medical Announces Investor Seminar
Futura Medical plc (AIM: FUM), a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) drug delivery technology and
currently focused on sexual health and pain, is pleased to announce
that it will be hosting an Investor Seminar on the 22 June 2023 in
London for analysts and institutional investors. Following the
Investor Seminar, an Investor Meet Company meeting will be held for
Retail Investors on Monday the 26 June.
The Investor Seminar follows a milestone year to date following
the UK launch on the 18 April 2023 of MED3000 under the brand name
Eroxon(R) with Cooper Consumer Health, its EU and UK distribution
partner, and online launches in Europe and in retail pharmacies in
Belgium.
The Investor Sseminar will feature presentations from Futura as
well as eminent Key Opinion Leaders (KOLs) Dr Jeff Foster, BSc,
(Hons), MB ChB, DRCOG, MRCGP, men's health specialist and book
author and Dr Janine David, FECSM, GP who specialises in Men and
Women's sexual health and will close with a presentation by Mark
Berkhout, International Marketing Director for Cooper Consumer
Health & Jon Connolly Marketing Director Ceuta Healthcare
For further information on the Investor Seminar, or to register
your interest, please contact Optimum Strategic Communications at
futuramedical@optimumcomms.com . Further information will be made
available closer to the event.
A recording will be made available through a webcast which can
be accessed via the investor section of the Futura website shortly
after the event. No new material disclosures will be made at the
event.
The Retail Investor event is scheduled for Monday 26 June at
10:00am with Investor Meet Company. Retail Investors can sign up to
Investor Meet Company for free via www.investormeetcompany.com
.
-ENDS-
For further information, please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Hollie Vile/ Jonathan Edwards/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Development and
commercialisation strategies are designed to maximise product
differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel
treatment for erectile dysfunction ("ED") through a unique
evaporative mode of action. Futura has previously conducted an
initial Phase 3 study using MED3000 in ED, referred to as "FM57"
which enabled Futura to be granted a CE Mark in 2021. A second
confirmatory Phase 3 clinical study, "FM71" was also conducted to
support Futura's regulatory submission to the FDA with 96 ED
patients and endpoints at 24 weeks, demonstrating that MED3000
presents an effective clinically proven treatment for ED with a
rapid speed of onset and a favourable benefit versus risk profile
ideally suited for an 'Over the Counter' classification.
Eroxon(R) is CE marked in Europe and UKCA marked in the UK as a
clinically proven topical treatment for adult men with erectile
dysfunction under the brand Eroxon(R), with a key claim of "Helps
you get an erection within 10 minutes". Eroxon(R) is the agreed
brand name in certain regions such as the EU whereas MED3000
continues to be the internal code name used by the Company and also
in reference
to countries where regulatory approval or commercial
distribution agreements have not yet been achieved. www.eroxon.com
.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange . www.futuramedical.com
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFRMLTMTTMBAJ
(END) Dow Jones Newswires
June 08, 2023 02:00 ET (06:00 GMT)
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
